索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]赵甜甜,张志星,赵慧,等.小檗碱改善心血管疾病的作用机制[J].国际心血管病杂志,2024,06:363-366.
点击复制

小檗碱改善心血管疾病的作用机制(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年06期
页码:
363-366
栏目:
综述
出版日期:
2024-12-10

文章信息/Info

Title:
-
作者:
赵甜甜; 张志星; 赵慧; 马甜甜; 冯兴韬; 程功
716099 延安大学医学院研究生院（赵甜甜，张志星）；710021 西安医学院研究生院（赵慧，马甜甜，冯兴韬）；710068 西安市红会医院心内科（程功）
Author(s):
-
关键词:
小檗碱; 心血管疾病; 作用机制
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.06.010
文献标识码:
-
摘要:
小檗碱（BBR）是从中药黄连等植物中分离得到的异喹啉类生物碱，可通过调节糖代谢和脂质代谢，预防心血管疾病的发生和进展。该文介绍BBR改善动脉粥样硬化、高血压、心律失常和心力衰竭等心血管疾病的作用机制。
Abstract:
-

参考文献/References

[1] Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J]. Nat Rev Cardiol, 2019, 16(4):203-212.
[2] Ma H, Wang X, Li X, et al. Adding salt to foods and risk of cardiovascular disease[J]. J Am Coll Cardiol, 2022, 80(23):2157-2167.
[3] Cai Y, Xin QQ, Lu JJ, et al. A new therapeutic candidate for cardiovascular diseases: berberine[J]. Front Pharmacol, 2021, 12:631100.
[4] Song DY, Hao JY, Fan DM. Biological properties and clinical applications of berberine[J]. Front Med, 2020, 14(5):564-582.
[5] Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective[J]. Endocrinol Metab Clin North Am, 2021, 50(3):337-355.
[6] Xie WT, Su FG, Wang GZ, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis[J]. Front Pharmacol, 2022, 13:1015045.
[7] Zhao MM, Lu J, Li S, et al. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel[J]. Nat Commun, 2021, 12(1):5616.
[8] Park HJ, Jung EY, Shim I. Berberine for appetite suppressant and prevention of obesity[J]. Biomed Res Int, 2020, 2020:3891806.
[9] Yu MY, Alimujiang M, Hu LL, et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex Ⅰin gut and liver[J]. Int J Biol Sci, 2021, 17(7):1693-1707.
[10] Wu CM, Zhao Y, Zhang YY, et al. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients[J]. J Adv Res, 2021, 37:197-208.
[11] Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis[J]. Int J Mol Sci, 2022, 23(6):3346.
[12] Jia DD, Zhang XY, Guo QQ, et al. Efficacy and underlying mechanism of berberine against atherosclerosis: a meta-analysis in preclinical animal studies[J]. J Cardiovasc Pharmacol, 2022, 80(3):476-488.
[13] Ma CY, Shi XY, Wu YR, et al. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway[J]. Ann Transl Med, 2021, 9(20):1517.
[14] Song T, Chen WD. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway[J]. Bioengineered, 2021, 12(1):8135-8146.
[15] Tan WX, Wang Y, Wang KY, et al. Improvement of endothelial dysfunction of berberine in atherosclerotic mice and mechanism exploring through TMT-based proteomics[J]. Oxid Med Cell Longev, 2020, 2020:8683404.
[16] Ma SR, Tong Q, Lin Y, et al. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota[J]. Signal Transduct Target Ther, 2022, 7(1):207.
[17] Yang SJ, Li D, Yu ZL, et al. Multi-pharmacology of berberine in atherosclerosis and metabolic diseases: potential contribution of gut microbiota[J]. Front Pharmacol, 2021, 12:709629.
[18] Man B, Hu CL, Yang GY, et al. Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE-/- mice[J]. Biochem Biophys Res Commun, 2022, 624:59-67.
[19] Di Palo KE, Barone NJ. Hypertension and heart failure:prevention, targets, and treatment[J]. Cardiol Clin, 2022, 40(2):237-244.
[20] Wang ZC, Wu F, Zhou QB, et al. Berberine improves vascular dysfunction by inhibiting trimethylamine-N-oxide via regulating the gut microbiota in angiotensin Ⅱ-induced hypertensive mice[J]. Front Microbiol, 2022, 13:814855.
[21] Wang ZC, Shao YJ, Wu F, et al. Berberine ameliorates vascular dysfunction by downregulating TMAO-endoplasmic reticulum stress pathway via gut microbiota in hypertension[J]. Microbiol Res, 2024, 287:127824.
[22] Zhang GX, Lin XF, Shao YJ, et al. Berberine reduces endothelial injury and arterial stiffness in spontaneously hypertensive rats[J]. Clin Exp Hypertens, 2020, 42(3):257-265.
[23] Wu JB, Nakashima S, Nakamura S, et al. Effects of sanoshashinto on left ventricular hypertrophy and gut microbiota in spontaneously hypertensive rats[J]. J Nat Med, 2020, 74(2):482-486.
[24] Tan N, Zhang Y, Zhang Y, et al. Berberine ameliorates vascular dysfunction by a global modulation of lncRNA and mRNA expression profiles in hypertensive mouse aortae[J]. PLoS One, 2021, 16(2):e0247621.
[25] Wang LL, Deng L, Lin N, et al. Berberine inhibits proliferation and apoptosis of vascular smooth muscle cells induced by mechanical stretch via the PDI/ERS and MAPK pathways[J]. Life Sci, 2020, 259:118253.
[26] Banaei P, Nazem F, Sedighi M. Investigation of the effect of 8 weeks of high-intensity interval training and berberine supplementation on some echocardiography and electrocardiogram indices following myocardial ischemia-reperfusion in rats[J]. ARYA Atheroscler, 2022, 18(4):1-9.
[27] Chen XY, Guo HC, Li Q, et al. Protective effect of berberine on aconite-induced myocardial injury and the associated mechanisms[J]. Mol Med Rep, 2018, 18(5):4468-4476.
[28] Zhang J, Wang Y, Jiang H, et al. Preventive effect of berberine on postoperative atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2022, 15(10):e011160.
[29] Hu HY, Zhou S, Sun XD, et al. A potent antiarrhythmic drug N-methyl berbamine extends the action potential through inhibiting both calcium and potassium currents[J]. J Pharmacol Sci, 2020, 142(4):131-139.
[30] Zheng HC, Zhu F, Miao PZ, et al. Antimicrobial natural product berberine is efficacious for the treatment of atrial fibrillation[J]. Biomed Res Int, 2017, 2017:3146791.
[31] Chen H, Chen YJ, Tang YH, et al. Berberine attenuates spontaneous action potentials in sinoatrial node cells and the currents of human HCN4 channels expressed in Xenopus laevis oocytes[J]. Mol Med Rep, 2014, 10(3):1576-1582.
[32] Wang LH, Yu CH, Fu Y, et al. Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model[J]. Phytother Res, 2011, 25(1):33-37.
[33] 孙玉, 郭守玉, 龙明智. 维利西呱治疗慢性心力衰竭的研究进展[J]. 国际心血管病杂志, 2023, 50(2):78-80.
[34] Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy[J]. Am J Cardiol, 2003, 92(2):173-176.
[35] Abudureyimu M, Yang MJ, Wang X, et al. Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca2＋ homeostasis in a murine model of HFpEF[J]. Front Med, 2023, 17(6):1219-1235.
[36] Abudureyimu M, Yu W, Cao RY, et al. Berberine promotes cardiac function by upregulating PINK1/Parkin-mediated mitophagy in heart failure[J]. Front Physiol, 2020, 11:565751.
[37] Liao Y, Chen KH, Dong XM, et al. Berberine inhibits cardiac remodeling of heart failure after myocardial infarction by reducing myocardial cell apoptosis in rats[J]. Exp Ther Med, 2018, 16(3):2499-2505.
[38] Long TY, Wei P, Fei L, et al. Berberine up-regulates miR-340-5p to protect myocardial ischaemia/reperfusion from HMGB1‐mediated inflammatory injury[J]. ESC heart Fail, 2023, 10(2):931-942.
[39] Yang KT, Chao TH, Wang IC, et al. Berberine protects cardiac cells against ferroptosis[J]. Tzu Chi Med J, 2022, 34(3):310-317. （收稿：2024-04-08 修回：2024-09-27）

备注/Memo

备注/Memo:
基金项目：恒心高血压/心肾保护医学研究基金（2022-CCA-HX-069）
通信作者：程功，E-mail：xianchenggong@163.com
更新日期/Last Update: 2024-12-10